Insider Selling: Karyopharm Therapeutics Inc. (KPTI) Insider Sells $103,900.00 in Stock

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) insider Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $10.39, for a total value of $103,900.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Karyopharm Therapeutics Inc. (NASDAQ KPTI) traded up $0.48 during midday trading on Monday, hitting $11.11. The stock had a trading volume of 204,500 shares, compared to its average volume of 234,501. Karyopharm Therapeutics Inc. has a fifty-two week low of $7.48 and a fifty-two week high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. sell-side analysts anticipate that Karyopharm Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in KPTI. Vanguard Group Inc. lifted its position in Karyopharm Therapeutics by 9.8% during the 1st quarter. Vanguard Group Inc. now owns 1,236,762 shares of the company’s stock worth $15,880,000 after acquiring an additional 110,093 shares in the last quarter. Geode Capital Management LLC lifted its position in Karyopharm Therapeutics by 7.8% during the 1st quarter. Geode Capital Management LLC now owns 168,770 shares of the company’s stock worth $2,167,000 after acquiring an additional 12,277 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Karyopharm Therapeutics by 5.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 275,972 shares of the company’s stock worth $3,543,000 after acquiring an additional 14,917 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in Karyopharm Therapeutics by 4.5% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 86,514 shares of the company’s stock worth $1,111,000 after acquiring an additional 3,762 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of Karyopharm Therapeutics by 0.7% in the 1st quarter. Bank of America Corp DE now owns 46,127 shares of the company’s stock valued at $592,000 after purchasing an additional 308 shares in the last quarter. 60.92% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts have commented on the company. Cantor Fitzgerald set a $18.00 price target on Karyopharm Therapeutics and gave the company a “buy” rating in a report on Thursday, October 12th. assumed coverage on Karyopharm Therapeutics in a report on Wednesday, November 15th. They issued a “buy” rating and a $23.00 price target for the company. Royal Bank Of Canada assumed coverage on Karyopharm Therapeutics in a report on Thursday, September 14th. They issued an “outperform” rating and a $14.00 price target for the company. Zacks Investment Research cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 7th. Finally, HC Wainwright restated a “buy” rating and issued a $23.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday, November 15th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $17.33.

COPYRIGHT VIOLATION NOTICE: “Insider Selling: Karyopharm Therapeutics Inc. (KPTI) Insider Sells $103,900.00 in Stock” was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark & copyright laws. The original version of this piece of content can be read at https://www.com-unik.info/2017/12/11/insider-selling-karyopharm-therapeutics-inc-kpti-insider-sells-103900-00-in-stock.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

What are top analysts saying about Karyopharm Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Karyopharm Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit